Qyuns Therapeutics Co., Ltd. Class H (HK:2509) has released an update.
Qyuns Therapeutics Co., Ltd. has announced successful Phase II clinical trial results for QX005N, a new injection treatment for Prurigo Nodularis (PN), at the 29th Annual Meeting of Chinese Society of Dermatology. The study demonstrated significant efficacy in itch relief and skin lesion improvement, with QX005N showing rapid action and good safety profile over a 24-week period. This breakthrough paves the way for addressing the substantial unmet clinical needs of approximately 2 million PN patients in China.
For further insights into HK:2509 stock, check out TipRanks’ Stock Analysis page.
